There are increasingly more bladder-sparing strategies for patients with even aggressive bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.
With new treatments and better risk stratification, there is increasingly more opportunity for bladder-sparing strategies in bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.
Transcript
What did you discuss in your session about organ preservation in patients with bladder cancer?
The best bladder is one's own, and what are the strategies in 2024 in actually saving one's bladder even when there's aggressive disease? We reviewed the state-of-the-art that is currently available, which is neoadjuvant chemotherapy and risk stratification and really predicting whether there is residual disease after chemotherapy and its challenges. For instance, there's a prospective trial1 that we did at the Fox Chase Cancer Center where we showed that that even though we would scrape the scar and do systematic biopsies and see nothing on endoscopic examination, about 25% of those patients harbored submucosal bladder cancer. And we talked about strategies of how to improve that prediction, but also discussed that if patients are appropriately stratified and appropriately counseled on the risks, there are opportunities to spare their bladders with or without delivering radiation to the bladder.
What advancements have we seen in bladder-sparing treatment?
The field has really been disrupted by enfortumab vedotin plus pembrolizumab data2 showing how remarkably superior those systemic therapy strategies are over cisplatin-based chemotherapy. This is in the metastatic setting, but now there are trials being done in the neoadjuvant setting [and] in the localized muscle-invasive setting. I think there's a lot of hope there that we can offer patients bladder-sparing approaches following systemic therapy, but that chapter is not yet written. The data are still not there, but clinically we're seeing incredible responses.
References
1. Zibelman M, Asghar AM, Parker DC. et al. Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial. J Urol. 2021;205(6):1605-1611. doi:10.1097/JU.0000000000001602
2. McNulty R. FDA approves enfortumab vedotin plus pembrolizumab for locally advanced or metastatic bladder cancer. The American Journal of Managed Care. December 18, 2023. Accessed May 7, 2024. https://www.ajmc.com/view/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-locally-advanced-or-metastatic-bladder-cancer
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen